Back to Exhibitors/Sponsors

Novartis Pharmaceuticals

About Novartis Pharmaceuticals

Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation. Xolair is FDA-approved across three diseases and in two formulations, continuing to build on the medicine's 17 years of patient experience since its initial approval for allergic asthma.